Research Topics
| Susan EshlemanSummaryAffiliation: Johns Hopkins University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
HIV surveillance in a large, community-based study: results from the pilot study of Project Accept (HIV Prevention Trials Network 043)Estelle Piwowar-Manning
Dept of Pathology, Johns Hopkins Univ, School of Medicine, Baltimore, MD, USA
BMC Infect Dis 11:251. 2011..We evaluated the accuracy of in-country HIV rapid testing and determined HIV prevalence in the Project Accept pilot study...- Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377)S H Eshleman
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
J Infect Dis 183:1732-8. 2001..Children who were maintained on their study regimen after virologic failure accumulated additional Nvp and 3TC mutations plus Rtv and Nfv mutations. However, Rtv and Nfv mutations were detected at unexpectedly low rates... - Limited evolution in the HIV type 1 pol region among acute seroconverters in Pune, IndiaSusan H Eshleman
The Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
AIDS Res Hum Retroviruses 21:93-7. 2005..Amino acid substitutions were rare, and varied from subject to subject. In this cohort, drug resistance was not observed and evolution in the pol region was very limited during the first 2 years of infection... - Analysis of Genetic Linkage of HIV From Couples Enrolled in the HIV Prevention Trials Network 052 TrialSusan H Eshleman
Department of Pathology, Johns Hopkins University, School of Medicine, Baltimore, Maryland
J Infect Dis 204:1918-26. 2011..This underscores the importance of assessing the genetic linkage of HIV seroconversion events in HIV prevention studies involving serodiscordant couples... - Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzerSusan H Eshleman
The Johns Hopkins Medical Institutions, Ross Building 646, 720 Rutland Ave, Baltimore, MD 21205, USA
J Clin Microbiol 43:813-7. 2005..This report supports the use of the ViroSeq system for identification of drug resistance mutations in HIV-1 protease and RT genes... - Analysis of HIV type 1 gp41 sequences in diverse HIV type 1 strainsSusan H Eshleman
Johns Hopkins University, School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 23:1593-8. 2007..The gp41 HIV-1 research reagents developed by Celera are useful tools for genotyping analysis of the gp41 region in diverse HIV-1 strains... - Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infectionSusan H Eshleman
Department of Pathology, Johns Hopkins University School of Medicine, The Johns Hopkins Medical Institutions, 720 Rutland Avenue, Baltimore, MD 21205, USA
AIDS 21:1165-74. 2007..We analyzed antiretroviral drug resistance, HIV-1 subtype, and HIV-1 tropism among 195 men who have sex with men from six major cities in the United States, using samples collected within 6 months of HIV-1 seroconversion (1999-2003)... - Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVPSusan H Eshleman
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
J Infect Dis 192:30-6. 2005..Here, we evaluate the rate of NVP resistance mutations in women with subtype C... - Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012Susan H Eshleman
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
J Acquir Immune Defic Syndr 39:593-7. 2005..To compare the rate of mother-to-child transmission (MTCT) in women with subtype A versus D HIV-1 who received single-dose nevirapine (NVP)... - Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012Susan H Eshleman
The Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
J Acquir Immune Defic Syndr 40:24-9. 2005..This study examined emergence and fading of specific NVPR mutations in women with these subtypes... - Association between the replication capacity and mother-to-child transmission of HIV-1, in antiretroviral drug-naive Malawian womenSusan H Eshleman
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
J Infect Dis 193:1512-5. 2006..45 for each 10% increase in replication capacity [95% confidence interval, 1.11-1.90]; P = .0063), after adjustment for maternal HIV-1 load and other factors... - Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1Susan H Eshleman
Johns Hopkins University, Baltimore, MD 21205, USA
J Infect Dis 193:479-81. 2006..20/23 [87%]; P < .001). The risk of MTCT of HIV-1 was comparable with these regimens. Infant-only prophylaxis also eliminates the development of NVP resistance in mothers... - Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, UgandaSusan H Eshleman
Department of Pathology, Johns Hopkins University School of Medicine, 646 Ross Bldg, 720 Rutland Ave, Baltimore, MD 21205, USA
AIDS 23:845-52. 2009..To analyze antiretroviral drug susceptibility in HIV from recently infected adults in Rakai, Uganda, prior to the availability of antiretroviral drug treatment... - Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assaySusan H Eshleman
School of Medicine, Johns Hopkins University, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 25:343-5. 2009..Mutations associated with other investigational HIV IN inhibitors were also identified. This suggests that HIV strains may vary in their natural susceptibility to HIV IN inhibitors... - Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012S H Eshleman
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 20:595-9. 2004..Complex patterns of NVPR are detected in some women. The Y181C NVPR mutation often fades from detection by 6-8 weeks. In contrast, the K103N mutation emerges more slowly, but often remains detectable 6-8 weeks after NVP... - Identification of Ugandan HIV type 1 variants with unique patterns of recombination in pol involving subtypes A and DSusan H Eshleman
Department of Pathology, Johns Hopkins Medical Institutions, Ross Building 646, 720 Rutland Avenue, Baltimore, MD 21205, USA
AIDS Res Hum Retroviruses 18:507-11. 2002..The large number of different types of pol recombinants identified suggests that recombination occurs readily in the pol region. Perinatal transmission of the recombinant viruses demonstrates their evolutionary stability... - Nevirapine resistance after single dose prophylaxisSusan H Eshleman
Department of Pathology, Johns Hopkins Medical Institutions, Ross Bldg 646, 720 Rutland Ave, Baltimore, MD 21205, USA
AIDS Rev 4:59-63. 2002..We review studies examining the emergence and fading of NVP-resistant HIV-1 in women and infants who received single dose NVP prophylaxis, and discuss the potential clinical relevance of NVP-resistance in this setting... - Survival of Ugandan infants with subtype A and D HIV-1 infection (HIVNET 012)Susan H Eshleman
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
J Acquir Immune Defic Syndr 31:327-30. 2002..We found no association between HIV-1 subtype (A vs. D) and infant survival in this cohort. Further studies are needed to evaluate whether HIV-1 subtype influences clinical outcome in pediatric HIV-1 infection... - Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutationsSusan H Eshleman
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 22:289-93. 2006..Further studies are needed to define the genetic correlates of antiretroviral drug resistance in nonsubtype B HIV-1... - Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assaySusan H Eshleman
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
J Acquir Immune Defic Syndr 52:121-4. 2009..We evaluated use of the ARCHITECT HIV Ag/Ab Combo assay (HIV Combo; Abbott Diagnostics; available for sale outside the United States only) for detection of acute HIV infection... - Analysis of HIV-1 variants by cloning DNA generated with the ViroSeq HIV-1 Genotyping SystemSusan H Eshleman
Department of Pathology, The Johns Hopkins Medical Institutions, Ross Bldg. 646, 720 Rutland Ave, Baltimore, MD 21205, USA
Biotechniques 35:614-8, 620, 622. 2003 - Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012)Susan H Eshleman
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
J Acquir Immune Defic Syndr 35:126-30. 2004..To compare the number and type of nevirapine (NVP) resistance mutations detected in Ugandan women with subtype A vs. D HIV-1 infection after single-dose NVP prophylaxis... - Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strainsSusan H Eshleman
Department of Pathology, The Johns Hopkins Medical Institutions, Ross Bldg 646, 720 Rutland Ave, Baltimore, MD 21205, USA
J Clin Microbiol 42:2711-7. 2004..8%). The ViroSeq system performs well for the analysis of plasma samples with diverse non-B subtypes. The availability of this genotyping system should facilitate studies of HIV-1 drug resistance in non-subtype B strains of HIV-1... - Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and DTamara S Flys
Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
J Acquir Immune Defic Syndr 42:610-3. 2006..Further studies are needed to evaluate the clinical significance of NVP-resistant variants in this setting... - Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1Megan Wind-Rotolo
Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
J Infect Dis 199:1301-9. 2009..Although resistant viruses fade to undetectable levels in plasma, they may persist as stably integrated proviruses within the latent reservoir in resting CD4(+) T cells, potentially complicating future treatment... - Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapineDana Jones
Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 21:319-24. 2005..Further studies are needed to evaluate whether selection of minority variants with one or more NVPR mutations after single-dose NVP is clinically relevant... - In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapineJessica D Church
Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 25:673-7. 2009..NVP resistance was still detected in some infants 6-12 months after sdNVP exposure. In this study, in utero HIV infection was the only factor associated with detection of NVP resistance in infants 6-8 weeks after sdNVP exposure... - Analysis of nevirapine resistance mutations in cloned HIV type 1 variants from HIV-infected Ugandan infants using a single-step amplification-sequencing method (AmpliSeq)William Ian Towler
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 24:1209-13. 2008..This analysis revealed numerous NVP resistance mutations not detected by population sequencing, genetically linked NVP resistance mutations, and a high degree of genetic complexity at codons that influence NVP susceptibility... - Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in UgandaWilliam I Towler
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 26:563-8. 2010..In Uganda, clinically and immunologically stable children receiving nonsuppressive antiretroviral treatment regimens are at risk for development of drug resistance... - Analysis of HIV type 1 gp41 and enfuvirtide susceptibility among men in the United States who were HIV infected prior to availability of HIV entry inhibitorsSarah E Hudelson
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 25:701-5. 2009..However, most of the mutations were not associated with phenotypic ENF resistance... - HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and DJessica D Church
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 23:764-8. 2007.... - Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmissionTamara S Flys
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
J Infect Dis 195:711-5. 2007..Fading (lack of detection) of K103N was documented in 16 women by 2 years, 43 women by 3 years, and 55 women by 4 and 5 years. Slower fading was independently associated with HIV-1 subtype (D>A) and higher pre-NVP viral load... - Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infantsJessica D Church
Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 25:657-63. 2009..LigAmp was useful for the detection and quantification of minority variants. PhenoSense HIV provided a direct and quantitative measure of NNRTI susceptibility... - Detection of K103N in Ugandan women after repeated exposure to single dose nevirapineTamara S Flys
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
AIDS 21:2077-82. 2007..Repeat use of SD NVP for pMTCT may influence emergence and persistence of NVP-resistant variants... - Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012Tamara Flys
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
J Infect Dis 192:24-9. 2005..Sensitive resistance assays may provide new insight into the impact of antiretroviral drug exposure on HIV-1 evolution... - Comparison of LigAmp and an ASPCR assay for detection and quantification of K103N-containing HIV variantsJessica D Church
Johns Hopkins University, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 24:595-605. 2008..Further studies are needed to compare performance of assays for detection and quantification of HIV drug resistance mutations in clinical samples... - Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and DJessica D Church
Department of Pathology, The Johns Hopkins Medical Institutions, Ross Bldg. 646, 720 Rutland Ave, Baltimore, MD 21205, USA
J Mol Diagn 8:430-2; quiz 527. 2006..Further studies are needed to compare the sensitivity of different assays for detection of HIV-1 drug resistance mutations and to determine the clinical relevance of HIV-1 minority variants... - Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newbornsSusan H Eshleman
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
AIDS 19:2167-9. 2005..Nevirapine resistance was more frequent in infants with subtype C than with subtypes A and D (87 versus 50%, P = 0.016)... - Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmissionJessica D Church
School of Medicine, Johns Hopkins University, Baltimore, Maryland 21205, USA
J Infect Dis 198:1075-82. 2008..We analyzed NVP resistance in HIV-infected Ugandan infants who received either SD NVP or extended NVP prophylaxis... - HIV-1 tropism and survival in vertically infected Ugandan infantsJessica D Church
Johns Hopkins University, Baltimore, Maryland, USA
J Infect Dis 197:1382-8. 2008..We analyzed HIV-1 coreceptor tropism in Ugandan infants enrolled in the HIVNET (HIV Network for Prevention Trials) 012 trial... - LigAmp for sensitive detection of single-nucleotide differencesChanjuan Shi
Department of Pathology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, Maryland 21205, USA
Nat Methods 1:141-7. 2004..Preliminary evidence indicates that reactions can be multiplexed. This assay may find applications in the diagnosis of genetic disorders and the management of patients with cancer and infectious diseases... - One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, IndiaAmita Gupta
Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
AIDS Res Hum Retroviruses 26:25-31. 2010..This emphasizes the need for greater viral load and resistance monitoring, use of optimal ART combinations, and increased availability of second- and third-line agents for patients with ARV resistance... - Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trialCharles Flexner
Johns Hopkins University, Baltimore, Maryland, USA
Clin Infect Dis 50:1041-52. 2010..Clinical trial registration. ClinicalTrials.gov registration number: NCT00036452... - Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmissionTamara S Flys
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
J Infect Dis 198:465-9. 2008..NVP resistance was detected in a similar proportion of infants born to SD NVP-naive versus SD NVP-experienced women. Repeated use of SD NVP to prevent HIV transmission does not appear to influence NVP resistance... - Pregnancy does not affect HIV incidence test results obtained using the BED capture enzyme immunoassay or an antibody avidity assayOliver Laeyendecker
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
PLoS ONE 5:e13259. 2010..Accurate incidence estimates are needed for surveillance of the HIV epidemic. HIV surveillance occurs at maternal-child health clinics, but it is not known if pregnancy affects HIV incidence testing... - Analysis of HIV diversity using a high-resolution melting assayWilliam I Towler
Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 26:913-8. 2010..111). The HRM assay provides a novel, rapid method for assessing HIV diversity without sequencing. This assay could be applied to any region of the HIV genome or to other genetic systems that exhibit DNA diversity... - Analysis of length variation in the V1-V2 region of env in nonsubtype B HIV type 1 from UgandaAlexandra M Klevytska
Department of Pathology, Johns Hopkins Medical Institutions, Ross Building 646, 720 Rutland Avenue, Baltimore, MD 21205, USA
AIDS Res Hum Retroviruses 18:791-6. 2002..This assay may be helpful for studies examining the impact of env length diversity on HIV-1 transmission and pathogenesis in regions where these subtypes are prevalent... - Mother-to-child transmission in the United States of subtypes D and A/G human immunodeficiency virus type 1Paul Krogstad
Department of Pediatrics, University of California Los Angeles School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
AIDS Res Hum Retroviruses 18:413-7. 2002..Non-B subtypes should be considered in the management of HIV-1-infected pregnant women and children to optimize strategies to prevent and treat pediatric HIV-1 infection... - A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus diseaseMargaret A Fischl
Department of Medicine, University of Miami School of Medicine, Miami, Florida 33101, USA
J Infect Dis 188:625-34. 2003..A 4-drug regimen containing efavirenz plus indinavir resulted in a superior virologic response, whereas one containing nelfinavir plus indinavir resulted in an inferior response and a greater likelihood of toxicity... - Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and DSusan H Eshleman
J Acquir Immune Defic Syndr 42:518-21. 2006 - Evaluation of the editing process in human immunodeficiency virus type 1 genotypingDiana D Huang
Department of Immunology Microbiology, Rush Medical College, Chicago, Illinois 60612, USA
J Clin Microbiol 41:3265-72. 2003..These results indicate a need for standardized editing guidelines in genotyping assays. Proficiency in editing should be assessed in training and included in quality control programs for HIV-1 genotyping... - Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter?Michelle S McConnell
Thailand US Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand
Am J Obstet Gynecol 197:S56-63. 2007..Further research in the optimization of perinatal prevention regimens is needed... - Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIVAnn C Collier
University of Washington School of Medicine and Harborview Medical Center, Seattle, Washington 98104, USA
HIV Clin Trials 9:91-102. 2008.... - Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populationsWei Huang
Monogram Biosciences, 345 Oyster Point Blvd, South San Francisco, CA 94080, USA
J Virol 81:7885-93. 2007.... - Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected womenKenneth H Mayer
Miriam Hospital Brown University, Providence, Rhode Island 02906, USA
AIDS 20:543-51. 2006.... - HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388Lisa M Demeter
Infectious Diseases Unit, University of Rochester, Rochester, New York 14642, USA
Clin Infect Dis 39:552-8. 2004..Thus, although dual resistance to efavirenz and lamivudine occurred at VF in the efavirenz-indinavir arm, this risk was relatively low when evaluated in the context of the potency and tolerability of this regimen... - Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 monthsAvinash K Shetty
Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
J Acquir Immune Defic Syndr 34:482-90. 2003..A phase 3 study is planned to assess the efficacy of OD infant NVP regimen to prevent breast-feeding HIV-1 transmission... - Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 resultsAngela Dm Kashuba
School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
AIDS 19:145-52. 2005..To evaluate fosamprenavir/lopinavir (LPV)/ritonavir (RTV), fosamprenavir/RTV, or LPV/RTV in antiretroviral treatment-experienced patients. Lack of drug interaction data prompted a pharmacokinetic substudy to minimize subject risk... - Analysis of insertions and deletions in the gag p6 region of diverse HIV type 1 strainsNatalia Marlowe
Celera Diagnostics, Alameda, California 94502, USA
AIDS Res Hum Retroviruses 20:1119-25. 2004..Further studies are needed to determine whether such genotypic differences influence viral replication capacity, antiretroviral drug susceptibility, or other phenotypic properties of these strains... - Analysis of PTAP duplications in the gag p6 region of subtype C HIV type 1Tamara Flys
AIDS Res Hum Retroviruses 21:739-41. 2005
Research Grants
- Drug Resistance in Non-Subtype B HIV-1Susan Eshleman; Fiscal Year: 2005..abstract_text> ..
- HIV Prevention Trials Network: Network LaboratorySusan Eshleman; Fiscal Year: 2007..Therefore, our agenda is complementary to long-term investments (finding a cure, vaccine, or microbicide). ..
- Impact of maternal HAART on HIV-infected breastfeeding infants: MalawiSusan H Eshleman; Fiscal Year: 2010..We will determine whether initiation of treatment in breastfeeding women poses any risk to breastfeeding infants who are HIV-infected, by inducing resistance to antiretroviral drugs in the infant's virus. ..